共 50 条
- [41] Sitagliptin, a selective DPP-4 inhibitor, improves glycemic control when added to a sulfonylurea or to a sulfonylurea and metformin in patients with type 2 diabetesDIABETES, 2007, 56 : A143 - A143Hermansen, KjeldKipnes, MarkLuo, EdmundFanurik, DebraKhatami, HootanStein, Peter P.
- [42] Sitagliptin added to ongoing treatment with metformin improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes (T2DM)DIABETES, 2008, 57 : A589 - A590Kadowaki, TakashiTajima, NaokoOdawara, MasatoNishii, MikioNonaka, KenjiStein, Peter P.
- [43] Sitagliptin added to ongoing treatment with glimepiride improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes (T2DM)DIABETES, 2008, 57 : A589 - A589Tajima, NaokoKadowaki, TakashiOdawara, MasatoNishii, MikioNonaka, KenjiStein, Peter P.
- [44] Effects of Dapagliflozin (DAPA), a Sodium Glucose Cotransporter 2 Inhibitor, on 24-Hour Glycemic Control in Patients with Type 2 Diabetes (T2D)DIABETES, 2016, 65 : A311 - A311Henry, Robert R.Strange, PoulZhou, RongZhuplatov, Sergey B.Mansfield, TraciKlein, DavidKatz, Arie
- [45] Initial combination therapy with sitagliptin, a selective DPP-4 inhibitor, and metformin leads to marked improvement in β cell function in patients with type 2 diabetesDIABETOLOGIA, 2007, 50 : S365 - S365Xu, L.Williams-Herman, D. E.
- [46] Initial combination therapy with sitagliptin, a selective DPP-4 inhibitor, and metformin leads to marked improvement in β-cell function in patients with type 2 diabetesDIABETES, 2007, 56 : A142 - A142Williams-Herman, DeboraXu, Lei
- [48] Dipeptidyl Peptidase-4 (Dpp-4) Inhibitor (Sitagliptin) as a Novel Treatment Agent for Nonalcoholic Fatty Liver Disease Patients With Type 2 Diabetes MellitusGASTROENTEROLOGY, 2012, 142 (05) : S1017 - S1017Tomeno, WataruYoneda, MasatoImajo, KentoMawatari, HironoriKirikoshi, HiroyukiSaito, SatoruShibata, WataruYoneda, KyokoEndo, HirokiKubota, KensukeNakajima, Atsushi
- [49] Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitusDIABETES OBESITY & METABOLISM, 2010, 12 (04): : 323 - 333Aaboe, K.Knop, F. K.Vilsboll, T.Deacon, C. F.Holst, J. J.Madsbad, S.Krarup, T.
- [50] Personality, Self-Management Behaviors, and Glycemic Control among Japanese Patients with Type 2 Diabetes Mellitus (T2DM)DIABETES, 2019, 68Morikawa, Sakiko Y.Fujihara, KazuyaHatta, MarikoTakeda, YasunagaIshii, DaiYachida, JunkoHorikawa, ChikaKato, MitsutoshiMaegawa, HiroshiSone, Hirohito